<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01413906</url>
  </required_header>
  <id_info>
    <org_study_id>CA194-010</org_study_id>
    <nct_id>NCT01413906</nct_id>
  </id_info>
  <brief_title>Phase 1 Multiple Ascending Dose Study of BMS-833923 (XL139) in Subjects With Solid Tumors</brief_title>
  <official_title>Phase 1 Multiple Ascending Dose Study of BMS-833923 (XL139) in Subjects With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the tolerability and safety profile of BMS-833923
      (XL139) when orally administered on a once daily schedule.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Dose Limiting Toxicity (DLT) and observed adverse events</measure>
    <time_frame>Within the first 28 days of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Dose Limiting Toxicity (DLT) and observed adverse events</measure>
    <time_frame>Up to 90 days additional treatment period plus 60 days of follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of subjects experienced DLT</measure>
    <time_frame>Within the first 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration (Cmax) of BMS-833923 (XL139)</measure>
    <time_frame>Day1 and Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough observed concentration (Cmin) of BMS-833923 (XL139)</measure>
    <time_frame>Day1 and Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed concentration (Tmax) of BMS-833923 (XL139)</measure>
    <time_frame>Day1 and Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve in one dosing interval [AUC(TAU)] of BMS-833923 (XL139)</measure>
    <time_frame>Day1 and Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effective half-life (T-half,eff) of BMS-833923 (XL139)</measure>
    <time_frame>Day1 and Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation index (AI) of BMS-833923 (XL139)</measure>
    <time_frame>Day1 and Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall response assessed according to Response evaluation criteria in solid tumors (RECIST) v1.1 criteria</measure>
    <time_frame>Up to120 days of treatment period</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1: BMS-833923 (XL139)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-833923 (XL139)</intervention_name>
    <description>Capsule, Oral, 150 mg, 300 mg, or 450 mg,Once daily, Until progression of disease, unacceptable toxicity, withdrawal of subject's consent or meeting other discontinuation criteria</description>
    <arm_group_label>Arm 1: BMS-833923 (XL139)</arm_group_label>
    <other_name>(XL139)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with advanced or metastatic solid tumors refractory to, or relapsed from,
             standard therapies or for which there is no known effective treatment

          -  Men and woman, 20 years of age and above

        Exclusion Criteria:

          -  Subjects with symptomatic brain metastasis or active brain metastasis requiring
             treatments

          -  Inability to swallow oral medication

          -  Uncontrolled or significant cardiovascular disease

          -  Inadequate bone marrow function

          -  Inadequate hepatic function

          -  Inadequate renal function

          -  Pancreatitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kashiwa-shi</city>
        <state>Chiba</state>
        <zip>2778577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2011</study_first_submitted>
  <study_first_submitted_qc>August 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2011</study_first_posted>
  <last_update_submitted>May 31, 2013</last_update_submitted>
  <last_update_submitted_qc>May 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

